BeyondSpring Hit With Second Nasdaq Delisting Notice — Now Fails Market Value Rule
BYSI sits 41% above its 52-week low of $0.566 on light trading volume (0.1× avg).
Summary
BeyondSpring received a second Nasdaq delisting notice for failing the $35 million market value requirement, adding to its existing bid-price deficiency. The company has until March 29, 2027 to regain compliance.
Key Events · Legal and Risk Events · BYSI
-
Second Nasdaq Delisting Notice
Nasdaq notified BeyondSpring on September 29, 2026 that its market value of listed securities fell below $35 million for 30 consecutive business days, violating Listing Rule 5550(b)(2).
-
Compliance Deadline Set
The company has 180 calendar days — until March 29, 2027 — to regain compliance by closing at $35 million MVLS or more for ten consecutive business days.
-
Compounding Listing Risk
This MVLS deficiency is separate from the bid-price delisting notice received September 17, 2026, meaning BeyondSpring now faces two simultaneous Nasdaq listing-compliance failures.
-
Recovery Hurdle
With a market cap near $32 million and shares around $0.80, regaining MVLS compliance requires a substantial share-price recovery — against a backdrop of going-concern doubt and the terminated Eli Lilly collaboration.
Analysis · BYSI · Life Sciences
BeyondSpring received a second, separate Nasdaq deficiency notice on September 29, 2026 — this time for its market value of listed securities falling below the $35 million minimum for 30 consecutive business days. This compounds the bid-price delisting notice from September 17, 2026. The company now faces two simultaneous listing-compliance failures, with a March 29, 2027 deadline to restore MVLS above $35 million for ten consecutive business days. With a market cap near $32 million and a stock price around $0.80, regaining compliance requires a substantial share-price recovery — a tall order given the going-concern warning and terminated Eli Lilly collaboration disclosed in the August 10-Q.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40% of the 1112 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BYSI was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.4M. The 52-week trading range was $0.57 to $2.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.